Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02095158 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
NCT02095158 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 440 participants.
The verdict
NCT02095158, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety and efficacy of oxymetazoline hydrogen chloride (HCL) Cream 1.0% (AGN-199201) in patients with persistent erythema associated with rosacea.
Interventions
- DRUG Oxymetazoline HCL Cream 1.0%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02095158
The ClinicalTrials.gov registry entry for NCT02095158 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxymetazoline HCL Cream 1.0% is the first listed.
NCT02095158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02095158 about?
NCT02095158 is a clinical study titled "A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea". This study will evaluate the long-term safety and efficacy of oxymetazoline hydrogen chloride (HCL) Cream 1.0% (AGN-199201) in patients with persistent erythema associated with rosacea.
What is the current status of trial NCT02095158?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2014-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02095158?
The interventions under investigation include: Oxymetazoline HCL Cream 1.0% (DRUG).
Who is sponsoring clinical trial NCT02095158?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.